The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
This article was originally published in RPM Report
Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.
You may also be interested in...
FDA “Program” Reviews Are Positive So Far, But Are They Sustainable?
Early feedback on FDA’s review “Program” for new drugs and biologics is cautiously optimistic. FDA is meeting user fee goals. Communication between reviewers and drug sponsors has dramatically improved. And even trickier applications have done unusually well at advisory committee meetings. But FDA’s John Jenkins acknowledges that a lack of resources is straining the system – and forcing the agency to adapt.
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.
The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard
After an almost two-year hiatus from strict adherence to the review timeframes set forth in the Prescription Drugs User Fee Act, Office of New Drugs Director John Jenkins has told the drug review staff that, once again, they should strive to meet the user fee deadlines